• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伏立康唑联合米卡芬净对念珠菌、曲霉菌、赛多孢属菌及茄病镰刀菌的作用。

Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.

作者信息

Heyn Kathrin, Tredup Antje, Salvenmoser Stefanie, Müller Frank-Michael C

机构信息

Department of Pediatrics III, Pediatric Pulmonology and Infectious Diseases, University of Heidelberg, Im Neuenheimer Feld 153, D-69120 Heidelberg, Germany.

出版信息

Antimicrob Agents Chemother. 2005 Dec;49(12):5157-9. doi: 10.1128/AAC.49.12.5157-5159.2005.

DOI:10.1128/AAC.49.12.5157-5159.2005
PMID:16304192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1315951/
Abstract

Effects of voriconazole combined with micafungin against 101 isolates of Candida spp. and 100 isolates of filamentous fungi have been evaluated by in vitro checkerboard analysis. The combination was indifferent for 97% of the Candida isolates and synergistic for 64% of the filamentous fungi (79% for Aspergillus fumigatus).

摘要

通过体外棋盘法分析评估了伏立康唑联合米卡芬净对101株念珠菌属菌株和100株丝状真菌的作用。该联合用药对97%的念珠菌分离株无相互作用，对64%的丝状真菌有协同作用（对烟曲霉为79%）。

相似文献

1
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.伏立康唑联合米卡芬净对念珠菌、曲霉菌、赛多孢属菌及茄病镰刀菌的作用。
Antimicrob Agents Chemother. 2005 Dec;49(12):5157-9. doi: 10.1128/AAC.49.12.5157-5159.2005.
2
Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.米卡芬净与伏立康唑联合用于曲霉属：一种检测体外联合抗真菌活性的药效学方法。
J Antimicrob Chemother. 2005 Nov;56(5):887-92. doi: 10.1093/jac/dki343. Epub 2005 Sep 27.
3
In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.两性霉素B与米卡芬净对赛多孢菌属的体外协同相互作用
Antimicrob Agents Chemother. 2005 Aug;49(8):3498-500. doi: 10.1128/AAC.49.8.3498-3500.2005.
4
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.通过美国国家临床实验室标准委员会（NCCLS）方法测定的阿尼芬净、米卡芬净（已获许可的药物）及研究性三唑类药物泊沙康唑对12052株真菌分离株的体外抗真菌活性：文献综述
Rev Iberoam Micol. 2003 Dec;20(4):121-36.
5
National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.日本念珠菌属血液分离株的物种分布及其对包括伏立康唑和米卡芬净在内的六种抗真菌药物的敏感性的全国监测。
J Antimicrob Chemother. 2004 Feb;53(2):283-9. doi: 10.1093/jac/dkh053. Epub 2003 Dec 19.
6
Determination of MICs of aminocandin for Candida spp. and filamentous fungi.氨基卡汀对念珠菌属和丝状真菌的最低抑菌浓度测定。
J Clin Microbiol. 2006 Dec;44(12):4342-4. doi: 10.1128/JCM.01550-06. Epub 2006 Oct 4.
7
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.阿尼芬净与伊曲康唑、伏立康唑及两性霉素B针对曲霉属和镰刀菌属进行的体外协同试验
Antimicrob Agents Chemother. 2005 Aug;49(8):3572-4. doi: 10.1128/AAC.49.8.3572-3574.2005.
8
In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.两性霉素B、伊曲康唑和伏立康唑对曲霉属、镰刀菌属和赛多孢菌属的体外药效学
Antimicrob Agents Chemother. 2005 Mar;49(3):945-51. doi: 10.1128/AAC.49.3.945-951.2005.
9
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.波氏假阿利什菌复合体各菌种的抗真菌药敏性
Antimicrob Agents Chemother. 2006 Dec;50(12):4211-3. doi: 10.1128/AAC.00981-06. Epub 2006 Oct 2.
10
In vitro interaction of micafungin and fluconazole against Candida.米卡芬净与氟康唑对念珠菌的体外相互作用。
J Antimicrob Chemother. 2007 Jul;60(1):188-90. doi: 10.1093/jac/dkm177. Epub 2007 May 24.

引用本文的文献

1
Successful management of septic arthritis and osteomyelitis in an immunocompetent child: A case report.免疫功能正常儿童脓毒性关节炎和骨髓炎的成功管理：一例报告
Med Mycol Case Rep. 2025 Apr 25;48:100704. doi: 10.1016/j.mmcr.2025.100704. eCollection 2025 Jun.
2
Systemic Infection Affecting Multiple Sites After Near-Drowning: A Case Report.近乎溺亡后多部位系统性感染：一例报告
Infect Drug Resist. 2024 Dec 20;17:5739-5744. doi: 10.2147/IDR.S483524. eCollection 2024.
3
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.新型抗真菌药物和治疗方法，以应对耐药性并改善侵袭性真菌感染的治疗结局。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074-23. Epub 2024 Apr 11.
4
Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.感染植物和人类的跨界真菌病原体以及唑类杀菌剂抗性问题。
Front Microbiol. 2024 Feb 12;15:1354757. doi: 10.3389/fmicb.2024.1354757. eCollection 2024.
5
Antifungal Combinations against Species: From Bench to Bedside.针对[具体物种]的抗真菌联合疗法：从实验室到临床应用
J Fungi (Basel). 2022 Oct 13;8(10):1077. doi: 10.3390/jof8101077.
6
Non- mould lung infections.非霉菌肺部感染。
Eur Respir Rev. 2022 Oct 19;31(166). doi: 10.1183/16000617.0104-2022. Print 2022 Dec 31.
7
Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis.基于洛维加和法及布利斯独立性的响应面分析对抗真菌组合与……物种相互作用的多中心协作研究
J Fungi (Basel). 2022 Sep 16;8(9):967. doi: 10.3390/jof8090967.
8
infection of the lumbar vertebrae: A case report.腰椎感染：一例报告。
World J Clin Cases. 2022 Apr 6;10(10):3251-3260. doi: 10.12998/wjcc.v10.i10.3251.
9
A Second-Generation Fungerp Analog, SCY-247, Shows Potent Activity against Candida auris and Other Clinically Relevant Fungal Isolates.第二代真菌哌仑西平类似物 SCY-247 对耳念珠菌和其他临床相关真菌分离株具有强大的活性。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01988-20.
10
fungemia successfully treated with voriconazole and terbinafine.伏立康唑和特比萘芬成功治疗真菌血症。
IDCases. 2020 Aug 8;22:e00928. doi: 10.1016/j.idcr.2020.e00928. eCollection 2020.

本文引用的文献

1
Voriconazole: therapeutic review of a new azole antifungal.伏立康唑：一种新型唑类抗真菌药物的治疗综述
Expert Rev Anti Infect Ther. 2004 Aug;2(4):485-97. doi: 10.1586/14787210.2.4.485.
2
Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.伏立康唑联合两性霉素B或米卡芬净在豚鼠侵袭性肺曲霉病模型中的疗效
Clin Microbiol Infect. 2004 Oct;10(10):925-8. doi: 10.1111/j.1469-0691.2004.00958.x.
3
Combination antifungal therapy.联合抗真菌治疗。
Antimicrob Agents Chemother. 2004 Mar;48(3):693-715. doi: 10.1128/AAC.48.3.693-715.2004.
4
Synergy, antagonism, and what the chequerboard puts between them.协同作用、拮抗作用，以及棋盘法介于两者之间的情况。
J Antimicrob Chemother. 2003 Jul;52(1):1. doi: 10.1093/jac/dkg301. Epub 2003 Jun 12.
5
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.联合治疗实验性肺曲霉病：抗真菌三唑类药物与棘白菌素之间的协同相互作用
J Infect Dis. 2003 Jun 15;187(12):1834-43. doi: 10.1086/375420. Epub 2003 Jun 4.
6
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.卡泊芬净与氟康唑和伊曲康唑相比，对3959株念珠菌属临床分离株（包括157株氟康唑耐药分离株）的体外活性。
Antimicrob Agents Chemother. 2003 Mar;47(3):1068-71. doi: 10.1128/AAC.47.3.1068-1071.2003.
7
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.卡泊芬净单独及与伏立康唑联合在豚鼠侵袭性曲霉病模型中的疗效。
Antimicrob Agents Chemother. 2002 Aug;46(8):2564-8. doi: 10.1128/AAC.46.8.2564-2568.2002.
8
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.三种新型三唑类药物和一种棘白菌素对癌症患者念珠菌血流分离株的体外活性。
J Antimicrob Chemother. 2002 Jul;50(1):119-23. doi: 10.1093/jac/dkf074.
9
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.伏立康唑治疗急性侵袭性曲霉病的疗效与安全性。
Clin Infect Dis. 2002 Mar 1;34(5):563-71. doi: 10.1086/324620. Epub 2002 Jan 22.
10
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.卡泊芬净与两性霉素B对曲霉属和镰刀菌属的体外协同作用
Antimicrob Agents Chemother. 2002 Jan;46(1):245-7. doi: 10.1128/AAC.46.1.245-247.2002.